Future directions in the prevention of prostate cancer

Nature Reviews Clinical Oncology

Volumn 11, Issue 1, 2014, Pages 49-60

  Thompson, Ian M ^a   Cabang, April B ^a   Wargovich, Michael J ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ATORVASTATIN; CASPASE 3; CELECOXIB; COLECALCIFEROL; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; FLUINDOSTATIN; GENISTEIN; IBUPROFEN; LYCOPENE; MELOXICAM; METFORMIN; MEVINOLIN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; POLYPHENOL; POLYPHENON E; PRAVASTATIN; PROTEIN BCL 2; RESVERATROL; ROSUVASTATIN; SELENIUM; SIMVASTATIN; STEROID 5ALPHA REDUCTASE INHIBITOR; SULINDAC; UNINDEXED DRUG; ANTIOXIDANT;

CANCER INCIDENCE; CANCER PREVENTION; CANCER RESEARCH; DIET THERAPY; DRUG EFFICACY; FOLLOW UP; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH; REVIEW; VALIDATION STUDY; CLINICAL TRIAL (TOPIC); FORECASTING; MALE; PRIMARY PREVENTION; PROCEDURES; PROSTATIC NEOPLASMS;

ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; FORECASTING; HUMANS; MALE; PRIMARY PREVENTION; PROSTATIC NEOPLASMS; SELENIUM; VITAMIN E;

EID: 84890984850     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.211     Document Type: Review

References (144)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
2. Haas, G. P. & Sakr, W. A. Epidemiology of prostate cancer. CA Cancer J. Clin. 47, 273-287 (1997).
3. Bell, F. C. & Miller, M. L. Life tables for the United States social security area 1900-2100. The United States Social Security Administration [online], http://www.ssa.gov/oact/NOTES/as120/LifeTables-Body.html (2005).
4. Carter, H. B. et al. Early detection of prostate cancer: AUA guideline. J. Urol. 190, 419-426 (2013).
5. Sanda, M. G. et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358, 1250-1261 (2008).
6. Moyer, V. A. & U. S. Preventive Services Task Force. Screening for prostate cancer: U. S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120-134 (2012).
7. National Cancer Institute. NCI Dictionary of Cancer Terms. National Cancer Institute [online], http://www.cancer.gov/dictionary?cdrid=45487.
8. Albanes, D. et al. Effects of α-tocopherol and β-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am. J. Clin. Nutr. 62 (Suppl. 6), 1427S-1430S (1995).
9. Clark, L. C. et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957-1963 (1996).
10. Lippman, S. M. et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J. Natl Cancer Inst. 97, 94-102 (2005).
11. [No authors listed] The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N. Engl. J. Med. 330, 1029-1035 (1994).
12. Klein, E. A. et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306, 1549-1556 (2011).
13. Bailey, R. L. et al. Dietary supplement use in the United States, 2003-2006. J. Nutr. 141, 261-266 (2011).
14. Dunn, B. K., Richmond, E. S., Minasian, L. M., Ryan, A. M. & Ford, L. G. A nutrient approach to prostate cancer prevention: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutr. Cancer 62, 896-918 (2010).
15. Marshall, J. R. et al. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev. Res. (Phila.) 4, 1761-1769 (2011).
16. Grino, P. B., Griffin, J. E. & Wilson, J. D. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126, 1165-1172 (1990).
17. Thompson, I. M., Coltman, C. A., Brawley, O. W. & Ryan, A. Chemoprevention of prostate cancer. Semin. Urol. 13, 122-129 (1995).
18. Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224 (2003).
19. Redman, M. W. et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev. Res. (Phila.) 1, 174-181 (2008).
20. Parsons, J. K. et al. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur. Urol. 62, 234-241 (2012).
21. Thompson, I. M. Jr et al. Long-term survival of participants in the prostate cancer prevention trial. N. Engl. J. Med. 369, 603-610 (2013).
22. Andriole, G. L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192-1202 (2010).
23. National Cancer Institute. The Prostate Cancer Prevention Trial. National Cancer Institute [online], http://www.cancer.gov/clinicaltrials/noteworthy- trials/pcpt/Page1 (2011).
24. Goodman, P. J. et al. Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev. Res. (Phila.) 3, 1523-1533 (2010).
25. Sfanos, K. S. & De Marzo, A. M. Prostate cancer and inflammation: the evidence. Histopathology 60, 199-215 (2012).
26. De Marzo, A. M. et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7, 256-269 (2007).
27. Johnson, C. S., Muindi, J. R., Hershberger, P. A. & Trump, D. L. The antitumor efficacy of calcitriol: preclinical studies. Anticancer Res. 26, 2543-2549 (2006).
28. Luo, W. et al. Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. Cancer Res. 73, 2289-2297 (2013).
29. Kaeding, J. et al. Calcitrol (1α, 25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells. Mol. Cancer Ther. 7, 380-390 (2008).
30. Lambert, J. R., Young, C. D., Persons, K. S. & Ray, R. Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells. Biochem. Biophys. Res. Commun. 361, 189-195 (2007).
31. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01759771 (2013).
32. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00887432 (2013).
33. Nelson, W. G., De Weese, T. L. & De Marzo, A. M. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev. 21, 3-16 (2002).
34. Nickel, J. C. et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur. Urol. 54, 1379-1384 (2008).
35. Eastham, J. A. et al. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J. Natl Cancer Inst. 90, 756-760 (1998).
36. Haverkamp, J., Charbonneau, B. & Ratliff, T. L. Prostate inflammation and its potential impact on prostate cancer: a current review. J. Cell. Biochem. 103, 1344-1353 (2008).
37. Guo, Y. Z., Pan, L., Du, C. J., Ren, D. Q. & Xie, X. M. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac. J. Cancer Prev. 14, 243-248 (2013).
38. Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
39. Mimeault, M. & Batra, S. K. Development of animal models underlining mechanistic connections between prostate inflammation and cancer. World J. Clin. Oncol. 4, 4-13 (2013).
40. Kristal, A. R. et al. Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am. J. Epidemiol. 172, 566-577 (2010).
41. Colli, J. L. & Amling, C. L. Chemoprevention of prostate cancer: what can be recommended to patients? Curr. Urol. Rep. 10, 165-171 (2009).
42. Khan, N., Afaq, F. & Mukhtar, H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid. Redox Signal. 10, 475-510 (2008).
43. Chou, R. et al. Screening for prostate cancer: a review of the evidence for the U. S. Preventive Services Task Force. Ann. Intern. Med. 155, 762-771 (2011).
44. Thompson, I. M. Jr et al. The Prostate Cancer Prevention Trial: current status and lessons learned. Urology 57 (Suppl. 1), 230-234 (2001).
45. Thompson, I. M. Chemoprevention of prostate cancer: lessons learned. BJU Int. 100 (Suppl. 2), 15-17 (2007).
46. Sporn, M. B. & Liby, K. T. Is lycopene an effective agent for preventing prostate cancer? Cancer Prev. Res. (Phila.) 6, 384-386 (2013).
47. Haseen, F., Cantwell, M. M., O'Sullivan, J. M. & Murray, L. J. Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review. Prostate Cancer Prostatic Dis. 12, 325-332 (2009).
48. Sporn, M. B. et al. Platforms and networks in triterpenoid pharmacology. Drug Dev. Res. 68, 174-182 (2007).
49. Ozten-Kandaş, N. & Bosland, M. C. Chemoprevention of prostate cancer: natural compounds, antiandrogens, and antioxidants - in vivo evidence. J. Carcinog. 10, 27 (2011).
50. National Cancer Institute. Clinical Trials Search Results. National Cancer Institute [online], http://www.cancer.gov/clinicaltrials/search/results? protocolsearchid=12022298 (2013).
51. Messina, M. Insights gained from 20 years of soy research. J. Nutr. 140, 2289S-2295S (2010).
52. Hwang, Y. W., Kim, S. Y., Jee, S. H., Kim, Y. N. & Nam, C. M. Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr. Cancer 61, 598-606 (2009).
53. Ide, H. et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 70, 1127-1133 (2010).
54. Hamilton-Reeves, J. M., Rebello, S. A., Thomas, W., Kurzer, M. S. & Slaton, J. W. Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr. Cancer 60, 7-13 (2008).
55. Lazarevic, B. et al. The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy. Br. J. Nutr. 108, 2138-2147 (2012).
56. Fleshner, N. E. et al. Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium. J. Clin. Oncol. 29, 2386-2390 (2011).
57. Wang, J., Eltoum, I. E. & Lamartiniere, C. A. Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Mol. Cell. Endocrinol. 219, 171-180 (2004).
58. Wang, J., Eltoum, I. E. & Lamartiniere, C. A. Genistein chemoprevention of prostate cancer in TRAMP mice. J. Carcinog. 6, 3 (2007).
59. Nakamura, H. et al. Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer. PLoS ONE 6, e20034 (2011).
60. Van Poppel, H. & Tombal, B. Chemoprevention of prostate cancer with nutrients and supplements. Cancer Manag. Res. 3, 91-100 (2011).
61. McCormick, D. L., Johnson, W. D., Bosland, M. C., Lubet, R. A. & Steele, V. E. Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Nutr. Cancer 57, 184-193 (2007).
62. Hasima, N. & Aggarwal, B. B. Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment. Curr. Med. Chem. (in press).
63. Anand, P., Kunnumakkara, A. B., Newman, R. A. & Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807-818 (2007).
64. Sundram, V., Chauhan, S. C., Ebeling, M. & Jaggi, M. Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS ONE 7, e35368 (2012).
65. Shankar, S., Ganapathy, S., Chen, Q. & Srivastava, R. K. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol. Cancer 7, 16 (2008).
66. Slusarz, A. et al. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 70, 3382-3390 (2010).
67. Barve, A. et al. Murine prostate cancer inhibition by dietary phytochemicals - curcumin and phenyethylisothiocyanate. Pharm. Res. 25, 2181-2189 (2008).
68. Killian, P. H. et al. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis 33, 2507-2519 (2012).
69. Boztas, A. O. et al. Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells. Mol. Pharm. 10, 2676-2683 (2013).
70. Sharma, R. A., Steward, W. P. & Gescher, A. J. Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol. 595, 453-470 (2007).
71. Zhongfa, L. et al. Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother. Pharmacol. 69, 679-689 (2012).
72. Shaikh, J., Ankola, D. D., Beniwal, V., Singh, D. & Kumar, M. N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci. 37, 223-230 (2009).
73. Moorthi, C., Krishnan, K., Manavalan, R. & Kathiresan, K. Preparation and characterization of curcumin-piperine dual drug loaded nanoparticles. Asian Pac. J. Trop. Biomed. 2, 841-848 (2012).
74. Yu, H., Li, J., Shi, K. & Huang, Q. Structure of modified e-polylysine micelles and their application in improving cellular antioxidant activity of curcuminoids. Food Funct. 2, 373-380 (2011).
75. Yu, H. & Huang, Q. Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions. J. Agric. Food Chem. 60, 5373-5379 (2012).
76. Jin, L. et al. Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells. Oncol. Rep. 29, 1983-1990 (2013).
77. Davalli, P. et al. Chronic administration of green tea extract to TRAMP mice induces the collapse of golgi apparatus in prostate secretory cells and results in alterations of protein post-translational processing. Int. J. Oncol. 39, 1521-1527 (2011).
78. Michaud, D. S. et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res. 66, 4525-4530 (2006).
79. McLarty, J. et al. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev. Res. (Phila.) 2, 673-682 (2009).
80. Hsu, A. et al. Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFκB pathway in the Noble rat model. J. Nutr. Biochem. 22, 502-510 (2011).
81. Adhami, V. M. et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin. Cancer Res. 15, 1947-1953 (2009).
82. Siddiqui, I. A. et al. Suppression of NF-κB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharm. Res. 25, 2135-2142 (2008).
83. Yang, C. S. et al. Cancer prevention by tea: evidence from laboratory studies. Pharmacol. Res. 64, 113-122 (2011).
84. Venkateswaran, V. & Klotz, L. H. Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat. Rev. Urol. 7, 442-453 (2010).
85. Brausi, M., Rizzi, F. & Bettuzzi, S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur. Urol. 54, 472-473 (2008).
86. Zheng, J. et al. Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. Nutr. Cancer 63, 663-672 (2011).
87. Aljada, A. & Mousa, S. A. Metformin and neoplasia: implications and indications. Pharmacol. Ther. 133, 108-115 (2012).
88. Belda-Iniesta, C., Pernia, O. & Simó, R. Metformin: a new option in cancer treatment. Clin. Transl. Oncol. 13, 363-367 (2011).
89. Lehman, D. M., Lorenzo, C., Hernandez, J. & Wang, C. P. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 35, 1002-1007 (2012).
90. Wright, J. L. & Stanford, J. L. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20, 1617-1622 (2009).
91. Azoulay, L., Dell'Aniello, S., Gagnon, B., Pollak, M. & Suissa, S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol. Biomarkers Prev. 20, 337-344 (2011).
92. Cohen, P. Metformin for the prevention of androgen deprivation induced metabolic syndrome, obesity and type 2 diabetes. Med. Hypotheses 72, 227-228 (2009).
93. Currie, C. J., Poole, C. D. & Gale, E. A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52, 1766-1777 (2009).
94. Currie, C. J. et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35, 299-304 (2012).
95. Decensi, A. et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. (Phila.) 3, 1451-1461 (2010).
96. Moyad, M. A. Re: A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. Eur. Urol. 61, 623-624 (2012).
97. Soranna, D. et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17, 813-822 (2012).
98. Zhang, P., Li, H., Tan, X., Chen, L. & Wang, S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 37, 207-218 (2013).
99. Kisfalvi, K., Moro, A., Sinnett-Smith, J., Eibl, G. & Rozengurt, E. Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas 42, 781-785 (2013).
100. Wu, B. et al. Metformin inhibits the development and metastasis of ovarian cancer. Oncol. Rep. 28, 903-908 (2012).
101. Vitale-Cross, L. et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev. Res. (Phila.) 5, 562-573 (2012).
102. Iliopoulos, D., Hirsch, H. A. & Struhl, K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 71, 3196-3201 (2011).
103. Chan, J. M., Feraco, A., Shuman, M. & Hernández-Díaz, S. The epidemiology of prostate cancer-with a focus on nonsteroidal anti-inflammatory drugs. Hematol. Oncol. Clin. North Am. 20, 797-809 (2006).
104. Kashfi, K. Anti-inflammatory agents as cancer therapeutics. Adv. Pharmacol. 57, 31-89 (2009).
105. Salinas, C. A. et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am. J. Epidemiol. 172, 578-590 (2010).
106. Stock, D., Groome, P. A. & Siemens, D. R. Inflammation and prostate cancer: a future target for prevention and therapy? Urol. Clin. North Am. 35, 117-130 (2008).
107. Mahmud, S. M. et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS ONE 6, e16412 (2011).
108. Harris, R. E. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17, 55-67 (2009).
109. Shebl, F. M. et al. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br. J. Cancer 107, 207-214 (2012).
110. Schenk, J. M. et al. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am. J. Epidemiol. 176, 156-163 (2012).
111. Veitonmaki, T., Tammela, T. L., Auvinen, A. & Murtola, T. J. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur. J. Cancer 49, 938-945 (2013).
112. Rothwell, P. M. et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379, 1591-1601 (2012).
113. Zhang, Y. et al. A novel sulindac derivative lacking cyclooxygenase- inhibitory activities suppresses carcinogenesis in the transgenic adenocarcinoma of mouse prostate model. Cancer Prev. Res. (Phila.) 3, 885-895 (2010).
114. Coogan, P. F., Kelly, J. P., Strom, B. L. & Rosenberg, L. Statin and NSAID use and prostate cancer risk. Pharmacoepidemiol. Drug Saf. 19, 752-755 (2010).
115. Zheng, X. et al. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev. Res. (Phila.) 3, 114-124 (2010).
116. Athar, M., Back, J. H., Kopelovich, L., Bickers, D. R. & Kim, A. L. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 486, 95-102 (2009).
117. Hsieh, T. C. & Wu, J. M. Resveratrol: biological and pharmaceutical properties as anticancer molecule. Biofactors 36, 360-369 (2010).
118. Klempner, S. J. & Bubley, G. Complementary and alternative medicines in prostate cancer: from bench to bedside? Oncologist 17, 830-837 (2012).
119. Fang, Y., DeMarco, V. G. & Nicholl, M. B. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Sci. 103, 1090-1098 (2012).
120. Fenner, A. Prostate cancer: resveratrol and apoptotic proteins enhance radiosensitivity. Nat. Rev. Urol. 9, 60 (2012).
121. Ganapathy, S., Chen, Q., Singh, K. P., Shankar, S. & Srivastava, R. K. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS ONE 5, e15627 (2010).
122. Seeni, A. et al. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac. J. Cancer Prev. 9, 7-14 (2008).
123. Sheth, S. et al. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS ONE 7, e51655 (2012).
124. Klink, J. C. et al. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate 73, 754-762 (2013).
125. Li, G. et al. Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis. Cancer Prev. Res. (Phila.) 6, 27-39 (2013).
126. Wang, T. T. et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 29, 2001-2010 (2008).
127. Neves, A. R., Lucio, M., Lima, J. L. & Reis, S. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Curr. Med. Chem. 19, 1663-1681 (2012).
128. Cottart, C. H., Nivet-Antoine, V., Laguillier-Morizot, C. & Beaudeux J. L. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 54, 7-16 (2010).
129. Narayanan, N. K., Nargi, D., Randolph, C. & Narayanan, B. A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer 125, 1-8 (2009).
130. Johnson, J. J. et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res. 55, 1169-1176 (2011).
131. Neves, A. R., Lúcio, M., Martins, S., Lima, J. L. & Reis, S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int. J. Nanomedicine 8, 177-187 (2013).
132. Santos, A. C., Veiga, F. & Ribeiro, A. J. New delivery systems to improve the bioavailability of resveratrol. Expert Opin. Drug Deliv. 8, 973-990 (2011).
133. Howells, L. M. et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. (Phila.) 4, 1419-1425 (2011).
134. Brown, V. A. et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 70, 9003-9011 (2010).
135. Popat, R. et al. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Brit. J. Haematol. 160, 714-717 (2013).
136. Bird, J. M. et al. Guidelines for the diagnosis and management of multiple myeloma. Br. J. Haematol. 154, 32-75 (2011).
137. Korbet, S. M. & Schwartz, M. M. Multiple myeloma. J. Am. Soc. Nephrol. 17, 2533-2545 (2006).
138. Nguyen, M. M. et al. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev. Res. (Phila.) 5, 290-298 (2012).
139. Colquhoun, A. J. et al. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 15, 346-352 (2012).
140. Ben Sahra, I. et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71, 4366-4372 (2011).
141. Ben Sahra, I. et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27, 3576-3586 (2008).
142. Dhillon, P. K., Kenfield, S. A., Stampfer, M. J. & Giovannucci, E. L. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006 Int. J. Cancer 128, 2444-2452 (2011).
143. Brizuela, L. et al. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. FASEB J. 24, 3882-3894 (2010).
144. Harper, C. E. et al. Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate 69, 1668-1682 (2009).